MCID: RST001
MIFTS: 54

Restless Legs Syndrome

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Restless Legs Syndrome

MalaCards integrated aliases for Restless Legs Syndrome:

Name: Restless Legs Syndrome 12 72 49 24 50 36 51 41 14 69 59
Restless Leg Syndrome 49 24
Willis-Ekbom Disease 12 24
Wed 12 24
Wittmaack-Ekbom Syndrome 12
Willis Ekbom Disease 49
Ekbom's Syndrome 24
Ekbom Syndrome 24
Restless Legs 40
Rls 24

Classifications:



External Ids:

Disease Ontology 12 DOID:0050425
ICD10 32 G25.81
ICD9CM 34 333.94
MeSH 41 D012148
NCIt 46 C84501
SNOMED-CT 64 32914008 393579008
KEGG 36 H01597
UMLS 69 C0035258

Summaries for Restless Legs Syndrome

NIH Rare Diseases : 49 Restless legs syndrome (RLS) is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, which occur mostly while the affected person is sitting or lying down and are worse at night. Movement (i.e. kicking, stretching, rubbing, or pacing) makes the discomfort go away, at least temporarily. Many people with restless legs syndrome also have uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. Researchers have described early-onset and late-onset forms of restless legs syndrome. The early-onset form begins before age 45 and progresses slowly. The late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly. RLS likely results from a combination of genetic and environmental factors, many of which are unknown. The syndrome may also be classified in several types (RLS1, RLS2, RLS3, RLS4, RLS5, RLS6, RLS7) according to the location in specific chromosomes of some of the genes that are associated with an increased risk (susceptibility) to have the syndrome.  Treatment is based on the signs and symptoms present in each person. Last updated: 5/5/2017

MalaCards based summary : Restless Legs Syndrome, also known as restless leg syndrome, is related to restless legs syndrome 6 and restless legs syndrome 7, and has symptoms including sleeplessness, excessive daytime somnolence and vertigo/dizziness. An important gene associated with Restless Legs Syndrome is RLS4 (Restless Legs Syndrome 4). The drugs Benzocaine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and kidney.

Disease Ontology : 12 A central nervous system disease characterized by throbbing, pulling creeping or other unpleasant sensations in the legs and the irresistible urge to move them.

Genetics Home Reference : 24 Restless legs syndrome is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, often described as crawling, pulling, or itching, deep within both legs. The feelings usually occur while the affected person is sitting or lying down and are worse at night. Movement, such as kicking, stretching, rubbing, or pacing, make the discomfort go away, at least temporarily. The unpleasant feelings and the resulting need to move the legs often make it difficult for an affected person to fall asleep or stay asleep.

MedlinePlus : 40 Restless legs syndrome (RLS) causes a powerful urge to move your legs. Your legs become uncomfortable when you are lying down or sitting. Some people describe it as a creeping, crawling, tingling, or burning sensation. Moving makes your legs feel better, but not for long. RLS can make it hard to fall asleep and stay asleep. In most cases, there is no known cause for RLS. In other cases, RLS is caused by a disease or condition, such as anemia or pregnancy. Some medicines can also cause temporary RLS. Caffeine, tobacco, and alcohol may make symptoms worse. Lifestyle changes, such as regular sleep habits, relaxation techniques, and moderate exercise during the day can help. If those don't work, medicines may reduce the symptoms of RLS. Most people with RLS also have a condition called periodic limb movement disorder (PLMD). PLMD is a condition in which a person's legs twitch or jerk uncontrollably, usually during sleep. PLMD and RLS can also affect the arms. NIH: National Heart, Lung, and Blood Institute

NINDS : 50 Restless legs syndrome (RLS) is characterized by unpleasant sensations in the legs and an irresistible urge to move them. Individuals affected with the disorder often describe the sensations as throbbing, polling, or creeping. The sensations range in severity from uncomfortable to irritating to painful. Symptoms commonly occur in late afternoon or evening and are most severe at night, when the person is resting. Moving the legs or walking typically relieves the discomfort but the symptoms often recur. RLS is both a sleep and a neurological sensory disorder.

PubMed Health : 59
About restless legs syndrome: Restless legs syndrome (RLS) is a disorder that causes a strong urge to move your legs. This urge to move often occurs with strange and unpleasant feelings in your legs. Moving your legs relieves the urge and the unpleasant feelings.People who have RLS describe the unpleasant feelings as creeping, crawling, pulling, itching, tingling, burning, aching, or electric shocks. Sometimes, these feelings also occur in the arms.The urge to move and unpleasant feelings happen when you're resting and inactive. Thus, they tend to be worse in the evening and at night.

Wikipedia : 72 Restless legs syndrome (RLS) is a disorder that causes a strong urge to move one\'s legs. There is often... more...

Related Diseases for Restless Legs Syndrome

Diseases related to Restless Legs Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 restless legs syndrome 6 34.8 BTBD9 RLS6
2 restless legs syndrome 7 34.7 MEIS1 RLS7
3 migraine with or without aura 1 30.9 DRD2 HCRT SLC6A3
4 narcolepsy 30.6 ATXN3 DRD2 HCRT SLC6A3
5 pathological gambling 30.5 DRD2 SLC6A3
6 parkinson disease, late-onset 30.4 ATXN3 DRD2 HCRT SLC6A3
7 rem sleep behavior disorder 30.2 HCRT SLC6A3
8 friedreich ataxia 1 30.2 ATXN3 FTMT TFRC
9 tic disorder 30.0 DRD2 SLC6A3
10 restless legs syndrome 2 12.6
11 restless legs syndrome 1 12.6
12 restless legs syndrome 4 12.5
13 restless legs syndrome 3 12.4
14 restless legs syndrome 5 12.4
15 restless legs syndrome 8 12.4
16 machado-joseph disease 11.4
17 sleep disorder 11.3
18 persistent genital arousal disorder 11.0
19 periodic limb movement disorder 10.6
20 reunion island larsen syndrome 10.5
21 alcohol-induced mental disorder 10.5 DRD2 SLC6A3
22 alcoholic psychosis 10.5 DRD2 SLC6A3
23 episodic pain syndrome, familial, 1 10.4
24 gilles de la tourette syndrome 10.4 BTBD9 DRD2 SLC6A3
25 striatonigral degeneration 10.4 DRD2 SLC6A3
26 neuropathy 10.3
27 disease of mental health 10.3 DRD2 HCRT SLC6A3
28 multiple sclerosis 10.3
29 oppositional defiant disorder 10.3 DRD2 SLC6A3
30 iron metabolism disease 10.2
31 central nervous system disease 10.2 ATXN3 HCRT SLC6A3
32 attention deficit-hyperactivity disorder 10.2
33 schizophrenia 10.2
34 aging 10.2
35 kidney disease 10.2
36 irritable bowel syndrome 10.2
37 headache 10.1
38 charcot-marie-tooth disease 10.1
39 chronic kidney failure 10.1
40 diabetic neuropathy 10.1
41 migraine with aura 10.1
42 tooth disease 10.1
43 impulse control disorder 10.1
44 essential tremor 10.1
45 tremor 10.1
46 heroin dependence 10.1 DRD2 SLC6A3
47 paine syndrome 10.0
48 ataxia and polyneuropathy, adult-onset 10.0
49 diabetes mellitus 10.0
50 sleep apnea 10.0

Graphical network of the top 20 diseases related to Restless Legs Syndrome:



Diseases related to Restless Legs Syndrome

Symptoms & Phenotypes for Restless Legs Syndrome

UMLS symptoms related to Restless Legs Syndrome:


sleeplessness, excessive daytime somnolence, vertigo/dizziness, chronic pain, tremor, syncope, snoring, sleep disturbances, seizures, sciatica, pain, headache, back pain

Drugs & Therapeutics for Restless Legs Syndrome

PubMedHealth treatment related to Restless Legs Syndrome: 59

Restless legs syndrome (RLS) has no cure. If a condition or medicine triggers RLS, it may go away or get better if the trigger is relieved or stopped.RLS can be treated. The goals of treatment are to:Prevent or relieve symptomsIncrease the amount of sleep you're getting and improve the quality of your sleepTreat or correct any underlying condition that may trigger or worsen RLSMild cases of RLS often are treated with lifestyle changes and sometimes with periodic use of medicines. More severe RLS usually is treated with daily medicines.

Drugs for Restless Legs Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
4
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 1 56-12-2 119
5
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 91374-20-8, 91374-21-9 5095 497540
9
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2 104632-26-0 119570 59868
10
Topiramate Approved Phase 4 97240-79-4 5284627
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
13
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
16
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 52485-79-7 644073 40400
17
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
18
Clopidogrel Approved Phase 4,Phase 3,Phase 2 120202-66-6, 113665-84-2 60606
19
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
20
Amitriptyline Approved Phase 4 50-48-6 2160
21
Donepezil Approved Phase 4 120014-06-4 3152
22
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
23
Memantine Approved, Investigational Phase 4 19982-08-2 4054
24
Propranolol Approved, Investigational Phase 4 525-66-6 4946
25
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
26
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
27
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
28
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
29
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 60857 441240
30 tannic acid Approved, Nutraceutical Phase 4,Phase 3
31
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 3 67-97-0 10883523 5280795 6221
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 1406-16-2
33 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
34 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1
36 N 0437 Phase 4,Phase 3,Phase 2
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
39 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
41 Antimanic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
43 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
44 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
46 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1
48 GABA Agents Phase 4,Phase 3,Phase 1
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 216)

# Name Status NCT ID Phase Drugs
1 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Unknown status NCT01823770 Phase 4 Rotigotine;Placebo patchs
2 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
3 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome Completed NCT00373542 Phase 4 ropinirole CR-RLS
4 Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment Completed NCT01981941 Phase 4 Gabapentin enacarbil
5 Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome Completed NCT02025608 Phase 4 Pramipexole;Placebo
6 Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4 ferric carboxymaltose
7 Long-term Study Of Ropinirole In Restless Legs Syndrome Completed NCT00329602 Phase 4 Placebo;Ropinirole
8 Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study Completed NCT01668667 Phase 4 GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
9 Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT00472199 Phase 4 Pramipexole;Placebo
10 Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Completed NCT01455012 Phase 4 Rotigotine;Placebo
11 Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome Completed NCT00200941 Phase 4 Topiramate
12 Switching From Oral Dopamine Agonists to Rotigotine Completed NCT01976871 Phase 4 Rotigotine
13 SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole Completed NCT00344994 Phase 4 pramipexole
14 A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS Completed NCT00349531 Phase 4 Pramipexole
15 A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS Completed NCT00375284 Phase 4 Pramipexole
16 Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances Completed NCT00356096 Phase 4 pramipexole
17 Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo Completed NCT00334048 Phase 4 Ropinirole (Requip)
18 Early Diuresis Following Colorectal Surgery Completed NCT02351934 Phase 4 Furosemide;Celecoxib;Gabapentin
19 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Recruiting NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
20 An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS Recruiting NCT02560766 Phase 4 HORIZANT 300 mg;HORIZANT 600 mg;Placebo
21 A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Recruiting NCT03053427 Phase 4 Gabapentin enacarbil;Placebo
22 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Recruiting NCT03082755 Phase 4 Gabapentin Enacarbil;Placebo Oral Tablet
23 An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS Enrolling by invitation NCT02633683 Phase 4 HORIZANT 600 mg
24 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
25 Migraine Prophylaxis With Clopidogrel Trial Not yet recruiting NCT02938182 Phase 4 clopidogrel
26 Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Terminated NCT02117076 Phase 4 Gabapentin immediate release;Gabapentin enacarbil extended release
27 Butrans for Treatment of Restless Legs Syndrome Withdrawn NCT02138357 Phase 4 buprenorphine transdermal delivery system (BTDS);Placebo for BTDS patch
28 Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome Withdrawn NCT00584246 Phase 4 Pregabalin (Lyrica);Placebo
29 RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI Withdrawn NCT02010437 Phase 4 Sodium Tetradecyl Sulphate (STS)
30 Vitamin D in the Treatment of Primary Restless Legs Syndrome Unknown status NCT02256215 Phase 2, Phase 3 Vitamin D
31 Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients Unknown status NCT00155441 Phase 3
32 A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors Unknown status NCT01895231 Phase 3 Iron isomaltoside 1000 (Monofer®);Placebo
33 Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients Completed NCT00806026 Phase 3 placebo and pregabalin;pramipexol;pramipexol;Pregabalin;pramipexol;pramipexol
34 Bupropion and Restless Legs Syndrome Completed NCT00621517 Phase 2, Phase 3 Bupropion;Placebo
35 Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT01569464 Phase 3 Rotigotine
36 Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Completed NCT02658188 Phase 3 ASP8825
37 RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole Completed NCT00314860 Phase 3 ropinirole Extended Release (XR)
38 Study of SPM 962 in Patients With Restless Legs Syndrome (RLS) Completed NCT01084551 Phase 3 SPM 962;SPM 962;Placebo of SPM 962
39 Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome Completed NCT00197080 Phase 3 Ropinirole Extended Release (XR)
40 Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance Completed NCT00991276 Phase 3 pregabalin;placebo;pramipexole
41 Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) Completed NCT00367822 Phase 3 Lisuride;Ropinirole;Placebo
42 An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome Completed NCT00263068 Phase 3 Rotigotine
43 Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) Completed NCT00256854 Phase 3 ropinirole controlled-release for RLS
44 A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS) Completed NCT00225862 Phase 3 ropinirole
45 Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects Completed NCT00498108 Phase 3 Rotigotine
46 Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome Completed NCT00355641 Phase 3 Ropinirole Extended Release (XR)
47 Sequential Compression Devices for Treatment of Restless Legs Syndrome Completed NCT00479531 Phase 3
48 Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00135993 Phase 3 Rotigotine
49 A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00275236 Phase 3 Rotigotine
50 Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS) Completed NCT00654498 Phase 3 Pramipexole;Placebo

Search NIH Clinical Center for Restless Legs Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: restless legs syndrome

Genetic Tests for Restless Legs Syndrome

Anatomical Context for Restless Legs Syndrome

MalaCards organs/tissues related to Restless Legs Syndrome:

38
Heart, Lung, Kidney, Testes, Brain, Spinal Cord, Bone

Publications for Restless Legs Syndrome

Articles related to Restless Legs Syndrome:

(show top 50) (show all 787)
# Title Authors Year
1
Altered Brain Functional Connectome in Migraine with and without Restless Legs Syndrome: A Resting-State Functional MRI Study. ( 29441041 )
2018
2
Restless Legs Syndrome in Iranian People With Type 2 Diabetes Mellitus: The Role in Quality of Life and Quality of Sleep. ( 29351820 )
2018
3
Chronic back pain cured by low-dose levodopa: is it a variant of restless legs syndrome? ( 29440925 )
2018
4
The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome. ( 29304922 )
2018
5
Restless Legs Syndrome/Willis-Ekbom Disease Is Prevalent in Working Nurses, but Seems Not to Be Associated with Shift Work Schedules. ( 29434568 )
2018
6
Acute-onset Restless legs syndrome in acute neurological conditions-a prospective study on patients with the Guillain-Barre syndrome and acute stroke. ( 29359321 )
2018
7
TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson's Disease with Opposite Effects. ( 29404899 )
2018
8
Diabetic Painful Neuropathy and Restless Legs Syndrome in Diabetes. ( 29427229 )
2018
9
Istradefylline for Restless Legs Syndrome Associated with Parkinson's Disease. ( 29423337 )
2018
10
Patients with primary restless legs syndrome have higher prevalence of autonomic dysfunction and irritable bowel syndrome. ( 29372261 )
2018
11
Association between serum hepcidin level and restless legs syndrome. ( 29418021 )
2018
12
Haplotype Association of the<i>MAP2K5</i>Gene with Antipsychotics-Induced Symptoms of Restless Legs Syndrome among Patients with Schizophrenia. ( 29422930 )
2018
13
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients. ( 29268951 )
2018
14
Leg Movement Activity during Sleep in School-Age Children and Adolescents: A Detailed Study in Normal Controls and Subjects with Restless Legs Syndrome and Narcolepsy Type 1. ( 29365206 )
2018
15
Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. ( 29425576 )
2018
16
Diurnal variation of default mode network in patients with restless legs syndrome. ( 29425573 )
2018
17
The prevalence of restless legs syndrome and its relationship with demographic characteristics and medical disorders in postmenopausal Iranian women. ( 29419360 )
2018
18
Restless Legs Syndrome: AnA Unresolved Uremic Disorder after Renal Transplantation. ( 29393274 )
2018
19
Insomnia and Psychopathological Features Associated With Restless Legs Syndrome in Chinese Adolescents. ( 29325239 )
2018
20
Association of BTBD9 and MAP2K5/SKOR1 With Restless Legs Syndrome in Chinese Population. ( 28329290 )
2017
21
Restless legs syndrome after high-risk TIA and minor stroke: association with reduced quality of life. ( 28899525 )
2017
22
Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. ( 28888061 )
2017
23
Characterizing restless legs syndrome and leg motor restlessness in patients with Parkinson's disease: A multicenter case-controlled study. ( 28827009 )
2017
24
Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review. ( 28886918 )
2017
25
The Role of Iron in Pediatric Restless Legs Syndrome and Periodic Limb Movements in Sleep. ( 28837991 )
2017
26
Sleep Disorders, Restless Legs Syndrome, and Uremic Pruritus: Diagnosis and Treatment of Common Symptoms in DialysisA Patients. ( 27693261 )
2017
27
Targeted disruption of supraspinal motor circuitry reveals a distributed network underlying Restless Legs Syndrome (RLS)-like movements in the rat. ( 28852150 )
2017
28
Pharmacological Management of Restless Legs Syndrome and Periodic Limb Movement Disorder in Children. ( 28831753 )
2017
29
Plantar reflex excitability is increased in the evening in restless legs syndrome patients. ( 28917979 )
2017
30
Motor hyperactivity of the iron-deficient rat - an animal model of restless legs syndrome. ( 28843017 )
2017
31
Restless legs syndrome is highly prevalent in patients with post-polio syndrome. ( 28899527 )
2017
32
Survival of Dialysis Patients with Restless Legs Syndrome: A 15-Year Follow-Up Study. ( 28869939 )
2017
33
Restless legs syndrome related to hemorrhage of a thoracic spinal cord cavernoma. ( 28899286 )
2017
34
Obesity: a possible risk factor for restless legs syndrome. ( 28944745 )
2017
35
Prevalence of restless legs syndrome during detoxification from alcohol and opioids. ( 28017182 )
2017
36
Restless legs syndrome in Parkinson disease: Clinical characteristics, abnormal iron metabolism and altered neurotransmitters. ( 28874701 )
2017
37
Uremic Restless Legs Syndrome Pleads "Not Guilty". ( 28869930 )
2017
38
Restless legs syndrome is contributing to fatigue and low quality of life levels in hemodialysis patients. ( 28948161 )
2017
39
Sleep Disorders: Restless Legs Syndrome. ( 28845959 )
2017
40
Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. ( 29358902 )
2017
41
Abnormal Sleep Delta Rhythm and Interregional Phase Synchrony in Patients with Restless Legs Syndrome and Their Reversal by Dopamine Agonist Treatment. ( 28831786 )
2017
42
Should oral iron be first-line therapy for pediatric restless legs syndrome and periodic limb movement disorder? ( 28279575 )
2017
43
While Isolated Periodic Limb Movement Disorder Significantly Impacts Sleep Depth and Efficiency, Co-Morbid Restless Leg Syndrome Mainly Exacerbates Perceived Sleep Quality. ( 28391285 )
2017
44
Restless legs syndrome and cerebrovascular/cardiovascular events: Systematic review and meta-analysis. ( 28948600 )
2017
45
Restless Bladder in an Elderly Woman: An Unusual Feature or a Variant of Restless Legs Syndrome? ( 27629973 )
2016
46
Higher nocturnal systolic blood pressure in patients with restless legs syndrome compared with patients with insomnia. ( 27908587 )
2016
47
Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor Use as a Predictor of a Diagnosis of Restless Legs Syndrome. ( 27427838 )
2016
48
Relationship between primary restless legs syndrome and migraine with aura. ( 27523456 )
2016
49
Do women with restless legs syndrome have less bone loss? ( 27022181 )
2016
50
Evaluation of neurodegeneration through visual evoked potentials in restless legs syndrome. ( 27053144 )
2016

Variations for Restless Legs Syndrome

Expression for Restless Legs Syndrome

Search GEO for disease gene expression data for Restless Legs Syndrome.

Pathways for Restless Legs Syndrome

GO Terms for Restless Legs Syndrome

Biological processes related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 temperature homeostasis GO:0001659 9.37 DRD2 HCRT
2 locomotory behavior GO:0007626 9.33 DRD2 MEIS1 SLC6A3
3 modulation of chemical synaptic transmission GO:0050804 9.32 BTBD9 DRD2
4 response to iron ion GO:0010039 9.26 DRD2 SLC6A3
5 prepulse inhibition GO:0060134 8.96 DRD2 SLC6A3
6 adenohypophysis development GO:0021984 8.62 DRD2 SLC6A3

Molecular functions related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine binding GO:0035240 8.62 DRD2 SLC6A3

Sources for Restless Legs Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....